Progra

Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting

GENEVA, July 11, 2007 /PRNewswire/ -- InspirationBiopharmaceuticals today announced the presentation of preclinicaldata supporting the development of new, proprietary forms ofrecombinant Factor IX to treat patients with Hemophilia B. The datawere highlighted in an oral presentation and a poster session atthe XXIst Congress of the International Society on Thrombosis andHaemostasis (ISTH)...

Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate

FREISING-WEIHENSTEPHAN, Germany, July 10, 2007 /PRNewswire/ --Pieris AG, a bio-pharmaceutical company developing Anticalins(R), anovel class of targeted human protein therapeutics, today announcedsignificant progress in validating novel, effective products forthe potential treatment of asthma. In studies of its proprietaryPRS-060 Anticalin(R) candidate, the Company reports that theprotei...

Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme

CAMBRIDGE, U.K. 2nd July 2007 - CeNeS Pharmaceuticals (AIM:CEN)("CeNeS" or "the Company") the Cambridge-based biopharmaceuticalcompany today announced that a paper published this week in CNSDrugs(1) further supports the hypothesis that acatechol-O-methyltransferase (COMT) inhibitor that acts in thebrain would be a useful agent to address profound cognitivedeficits in schizophrenia and bi...

Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2007 - ElixirPharmaceuticals, Inc., today announced the presentation of two setsof preclinical data demonstrating that ghrelin antagonism may be apotential method for future treatment of a range of metabolicdisorders. These data demonstrated a variety of beneficialmetabolic effects, notably decreasing body weight, improvements inblood glucose and i...

Pharmexa A/S (DK) - Pharmexa presents data from influenza program

Summary: Pharmexa-Epimmune, the U.S.-based subsidiary ofPharmexa A/S, presents selected data from its influenza vaccineprogram today at the Influenza Conference entitled, "Options forthe Control of Influenza VI," held in Toronto, Ontario, Canada. Thedata show that a "universal" vaccine designed to inducecell-mediated immune responses can protect transgenic mice againstlethal experimental...

Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007

SAN DIEGO, June 19, 2007 /PRNewswire-FirstCall/ -- AmylinPharmaceuticals, Inc. today announced that data featuring itsapproved diabetes drugs, BYETTA(R) (exenatide) injection andSYMLIN(R) (pramlintide acetate) injection, and its pipelinecandidates will be presented at the American Diabetes Association's(ADA) 67th Annual Scientific Sessions being held in Chicago, ILfrom June 22 to 26. The...

Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting

MONTREAL, QUEBEC--(CCNMatthews - June 14, 2007) - AmbriliaBiopharma Inc. (TSX:AMB), a biopharmaceutical company developingnovel small molecules and peptides to treat infectious diseases andcancer, held its Annual General and Special Meeting today, duringwhich the data reported yesterday on its novel series of HIVintegrase inhibitors and recent developments were highlighted. Themeeting wa...

CuraGen Presents Update on Clinical Development Program for Belinostat

- Clinical activity reported against CTCL, PTCL and Ovarian Cancers- BRANFORD, Conn., June 12, 2007 /PRNewswire-FirstCall/ -- CuraGenCorporation , a clinical-stage biopharmaceutical company focused ononcology, presented today an update on the clinical developmentprogram for belinostat, a histone deacetylase (HDAC) inhibitor, andreported updated results suggesting clinical activity of beli...

Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting

* Preclinical study evaluating a clinically relevant model ofnormal human skin found that Menadione was the only agent capableof abrogating the cytotoxic effect of erlotinib * Phase I singleagent Marqibo(r) showed OPTISOME(tm) agent was generally welltolerated in metastatic melanoma patients with an adverse eventprofile similar to conventional vincristine SOUTH SAN FRANCISCO, Calif...

Diatos Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program

PARIS--(BUSINESS WIRE)--Jun 4, 2007 - Diatos SA, an internationalbiopharmaceutical company focusing on the research, development andcommercialization of targeted anti-cancer drugs, today announcedthat they presented data from a Phase I clinical trial of theiranti-cancer compound, DTS-201, at the 43rd Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) in Chicago, USA. DTS-20...

OXiGENE Abstracts Published in ASCO Program

WALTHAM, Mass.--(BUSINESS WIRE)--Jun 1, 2007 - OXiGENE, Inc.(NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biopharmaceuticalcompany developing novel therapeutics to treat cancer and eyediseases, announced today the publication of two abstracts in the2007 Annual Meeting program distributed this afternoon at theAnnual Meeting of the American Society of Clinical Oncology (ASCO)in Chicago, IL.<p...

DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp

CUPERTINO, Calif., May 17, 2007 /PRNewswire-FirstCall/ -- DURECTCorporation announced today that Voyager Pharmaceutical hasprovided its shareholders with an update on its truncated Phase 3clinical trial for Memryte, an investigational drug for thetreatment of Alzheimer's disease. Voyager has informed itsshareholders that they have observed positive outcome trends amongwomen, but no posit...

SkyePharma and Sciele Pharma Announce Successful Completion of New Sular Formulation Clinical Trial Programme

LONDON, UK and ATLANTA, US, May 14, 2007 - SkyePharma PLC(LSE:SKP; NASDAQ:SKYE) and Sciele Pharma. Inc. (NASDAQ:SCRX) todayannounce the successful completion of the clinical trial programmefor the new formulation of Sular, a calcium channel blocking agent for the treatment of high blood pressure.The study results showed that the new Sular formulatio...

Sciele Pharma Announces Successful Completion of New Sular Formulation Clinical Trial Program

ATLANTA--(BUSINESS WIRE)--May 14, 2007--Sciele Pharma, Inc.(NASDAQ:SCRX) today announced the successful completion of theclinical trial program for its new Sular formulation. The studyresults showed that the new Sular formulation is bioequivalent toSciele's currently marketed Sular. The new Sular formulationutilizes SkyePharma's (LSE:SKP) patented Geomatrix technology,which is designed t...

Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting

Statistically Significant Improvements in Function in Spinal CordInjury Model With ZFP TF Treatment RICHMOND, Calif., May 03, 2007 /PRNewswire-FirstCall/ -- SangamoBioSciences, Inc. announced today the presentation of preclinicaldata from its ZFP Therapeutic(TM) program in nerve regeneration atthe Fourteenth Annual Conference of the American Society for NeuralTherapy and Repair. The data...

Quest PharmaTech's Prostate Cancer Program Update

Trading Symbol: QPT: TSX Venture Exchange EDMONTON, May 02, 2007 /PRNewswire-FirstCall/ - Quest PharmaTechInc. ("Quest" or the "Company") Quest is pleased to provide anupdate on the pre-clinical development of SL052 for the treatmentof prostate cancer. Prostate cancer is the second leading cause of cancer death inAmerican men with approximately 230,000 new cases and 30,000 deathspe...

Pediatric Academic Societies' Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV

GAITHERSBURG, Md., May 2 /PRNewswire-FirstCall/ -- MedImmune, Inc.(Nasdaq: MEDI) today announced that seven abstracts will bepresented at the 2007 Pediatric Academic Societies' (PAS) AnnualMeeting demonstrating the company's commitment to advancing thescience of pediatric medicine. Data are from studies pertaining toMedImmune's approved and development-stage products, including bothmonoclon...

Peregrine Pharmaceuticals Highlights Significant Advances in the Company's Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting

- New Study Demonstrated the Clinical Potential of Peregrine'sUnique Selective Anti-VEGF Antibodies, Which Were as Effective asAvastin(R) in Animal Cancer Models TUSTIN, Calif., April 20, 2007 /PRNewswire-FirstCall/ --Peregrine Pharmaceuticals, Inc. , a clinical stagebiopharmaceutical company developing targeted monoclonal antibodiesfor the treatment of cancer and hepatitis C virus infect...

Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting

1 EOquin Instillation Immediately Following Transurethral Resectionis Well Tolerated in Phase 2b Bladder Cancer Study IRVINE, Calif., April 19, 2007 /PRNewswire-FirstCall/ --Spectrum Pharmaceuticals, Inc., today announced results of a Phase2b study of EOquin, in non-invasive bladder cancer and thepresentation of preclinical data of SPI (IRL)-1620 and satraplatinat the annual meeting of th...

ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting

NEW YORK--(BUSINESS WIRE)--Apr 19, 2007 - IgG1 monoclonalantibodies developed by ImClone Systems Incorporated (NASDAQ: IMCL)were the focus of 44 total presentations at the recently concluded98th Annual Meeting of the American Association for Cancer Research(AACR), including seven oral presentations and 37 posters. Important ERBITUX(R) (cetuximab) clinical data were the focus oftwo back-to...

Innovive Pharmaceuticals Announces Preclinical Data from INNO-206 Oncology Program

NEW YORK--(BUSINESS WIRE)--Apr 18, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB:IVPH) announced data from preclinical evaluation of thecompany's drug candidate INNO-206, a doxorubicin prodrug fortreatment of a variety of tumor types. Researchers found thatINNO-206, a form of doxorubicin that attaches to circulatingalbumin and becomes activated once located at the tumor site, ismuch better to...

Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, 2007 - AlnylamPharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeuticscompany, announced today at the American Association for CancerResearch (AACR) 2007 Annual Meeting that it will advance asystemically delivered RNAi therapeutic, ALN-VSP01, for thetreatment of liver cancer and potentially other solid tumors as anew development program. A...

Data supporting three Antisoma programmes presented at AACR

LONDON, and LOS ANGELES, 16 April 2007- Antisoma announces thatpreclinical data supporting three of its drugs are presented thisweek at the Annual Meeting of the American Association of CancerResearch (AACR). AS1404-Avastin-paclitaxel triple combination highly effectiveAntisoma's scientists have for the first time evaluated a triplecombination of the Company's vascular disrupting a...

Rigel to Present New Research Programs at AACR Meeting

Focus on Rigel's Extensive Oncology Portfolio SOUTH SAN FRANCISCO, Calif., April 16, 2007/PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. todayannounced the presentation of four research projects aimed atidentifying small molecule inhibitors of select kinases aspotential therapeutics for certain types of cancers and otherdisorders. Rigel scientists will give the presentations during...

Innovive Pharmaceuticals Announces Data from Oncology Drug Programs to be Presented at American Association for Cancer Research Annual Meeting

NEW YORK--(BUSINESS WIRE)--Apr 10, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB:IVPH) today announced that interim data from a Phase Itrial of INNO-406, an orally bioavailable dual Bcr-Abl andLyn-kinase inhibitor for Gleevec-resistant or treatment-intolerantchronic myelogenous leukemia, will be presented at the AmericanAssociation for Cancer Research Annual Meeting. Additionally,preclinical...

Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimer's Research

In Vitro Assays Show rBChE Suppresses Amyloid PlaqueFormation ANNAPOLIS, Md., April 3, 2007 - PharmAthene, Inc., a leadingbiodefense company specializing in the development andcommercialization of medical countermeasures against chemical andbiological terrorism, announced today that new data from itsrecombinant butyrylcholinesterase (rBChE) research program wererecently presented...

PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimer's Research

In Vitro Assays Show rBChE Suppresses Amyloid Plaque Formation ANNAPOLIS, Md., April 03, 2007 /PRNewswire/ -- PharmAthene,Inc., a leading biodefense company specializing in the developmentand commercialization of medical countermeasures against chemicaland biological terrorism, announced today that new data from itsrecombinant butyrylcholinesterase (rBChE) research program wererecently pr...

NeoPharm Provides Update on LE-SN38 Program

WAUKEGAN, Ill.--(BUSINESS WIRE)--Mar 30, 2007 - NEOPHARM, Inc.(Nasdaq: NEOL) today reported findings from a Phase 2 clinicaltrial in second-line metastatic colorectal cancer patients with itsdrug product candidate LE-SN38, the active metabolite of irinotecan(Camptosar(R)). While the interim analysis of data following thecompletion of treatment of the first 21 patients demonstrateddisease st...

ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research

SAN DIEGO--(BUSINESS WIRE)--Mar 29, 2007 - ACADIA PharmaceuticalsInc. (Nasdaq: ACAD), a biopharmaceutical company utilizinginnovative technology to fuel drug discovery and clinicaldevelopment of novel treatments for central nervous systemdisorders, today announced that the company will present at the2007 International Congress on Schizophrenia Research, held fromMarch 28 through April 1, 20...

Biosite Reports on Presentation of Preliminary Data From Sepsis Program

SAN DIEGO and BRUSSELS, Belgium, March 28, 2007/PRNewswire-FirstCall/ -- Biosite Incorporated today announcedpreliminary results of a sample collection study aimed atidentifying a biomarker panel that could potentially aid in theassessment for risk of sepsis progression. Sepsis is an often fatalcondition with limited therapeutic options. Clinical investigator,Emanuel P. Rivers, M.D., MPH...

Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery

Largest Randomized Safety Program of Intravenous Antihypertensivesto Date Presented at ACC Scientific Sessions NEW ORLEANS, March 27, 2007 /PRNewswire-FirstCall/ -- Findingsfrom ECLIPSE**, the largest safety program comparing intravenousantihypertensive therapies, show that improved control ofperioperative hypertension -- a potentially harmful elevation inblood pressure just before, durin...

Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity

Rigel Program to be Presented at Keystone Scientific Meeting SOUTH SAN FRANCISCO, Calif., March 27, 2007/PRNewswire-FirstCall/ -- Rigel today announced that YonchuJenkins, Ph.D., Associate Director of Virology, will be presentingon the company's efforts to develop a small molecule therapeutic totreat patients with the Human Immunodeficiency Virus (HIV)infection at the Keystone Symposium i...

Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Mar 19, 2007 - AcordaTherapeutics (Nasdaq: ACOR) today announced that Andrew Goodman,M.D., Director of the Multiple Sclerosis Center at the Universityof Rochester, will present data from Acorda's MS-F203 Phase 3clinical trial of Fampridine-SR in multiple sclerosis at theupcoming American Academy of Neurology (AAN) meeting. The platformpresentation will take...

JACC Publishes Long-Term Safety and Tolerability Data from Ranolazine Open Label Experience (ROLE) Program

PALO ALTO, Calif., March 14, 2007 /PRNewswire-FirstCall/ -- CVTherapeutics, Inc. announced today that the Journal of the ofCardiology (JACC) has published data from the Ranolazine Open LabelExperience (ROLE) program, which showed long-term therapy withRanexa(R) (ranolazine extended-release tablets) to be safe and welltolerated in patients with chronic stable angina who completed oneof tw...